Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 22 | 1,127 | 45% |
| 2020 | 21 | 1,066 | 51% |
| 2021 | 14 | 950 | 55% |
| 2022 | 14 | 981 | 59% |
| 2023 | 13 | 918 | 63% |
| 2024 | 10 | 897 | 66% |
| 2025 from claims | – | 1,014 820–1,191 | 67% |
| 2026 forecast | – | 1,049 822–1,318 | 67% |
| 2027 forecast | – | 1,073 796–1,419 | 68% |
| 2028 forecast | – | 1,098 777–1,515 | 69% |
| 2029 forecast | – | 1,122 762–1,608 | 70% |
| 2030 forecast | – | 1,146 750–1,700 | 70% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Michigan; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 27% inpatient hospital, 73% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,000 | ~270 | ~780 |
| 2027 · ~1,100 | ~270 | ~800 |
| 2028 · ~1,100 | ~270 | ~820 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 25% (27% in 2025), hospital outpatient about 75% (73% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 19 | 1,532−1.5%/yr | −1.5%/yr | 1.5 | 0% | 1,790 in 2030+2.6%/yr |
| Illinois | 22 | 1,462−0.6%/yr | −0.6%/yr | 1.1 | 0% | 1,710 in 2030+2.7%/yr |
| Indiana | 17 | 989+0.3%/yr | +0.3%/yr | 1.5 | 0% | 1,570 in 2030+8%/yr |
| Missouri | 11 | 798−1.8%/yr | −1.8%/yr | 1.4 | 0% | 980 in 2030+3.5%/yr |
| Minnesota | 10 | 773+1.1%/yr | +1.1%/yr | 1.9 | 0% | 1,410 in 2030+11%/yr |
| Wisconsin | 15 | 741−1.7%/yr | −1.7%/yr | 1.5 | 0% | 1,000 in 2030+5.1%/yr |
| Kansas | 10 | 583−1.8%/yr | −1.8%/yr | 1.5 | 0% | 720 in 2030+3.6%/yr |
| Iowa | 8 | 457+1.6%/yr | +1.6%/yr | 1.1 | 0% | 470 in 2030+0.6%/yr |
| Nebraska | 9 | 452+0.8%/yr | +0.8%/yr | 1.8 | 0% | 520 in 2030+2.2%/yr |
| South Dakota | 8 | 299+3.3%/yr | +3.3%/yr | 2.5 | 0% | 560 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 94 | 4,688−5.4%/yr | −5.4%/yr | 5.61.0× | 6% | 4,480 in 2030−0.8%/yr |
| BPH procedures | 40 | 3,700−3.6%/yr | −3.6%/yr | 4.30.9× | 29% | 3,320 in 2030−1.8%/yr |
| Hysterectomy, hysteroscopy & ablation | 15 | 2,577−6%/yr | −6%/yr | 3.41.2× | 11% | 2,550 in 2030−0.1%/yr |
| Incontinence, prolapse & sacral neuromodulation | 25 | 1,789−6.7%/yr | −6.7%/yr | 2.10.9× | 4% | 1,480 in 2030−3.1%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Ohio
Intuitive Surgical leads with 98% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with Michigan’s surgeons worth $208K in consulting, speaking, meals and travel tied to these products, about $21K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.